Coronavirus pandemic has brought the world to a grinding halt and people across the globe are forced to stay indoors to prevent the spread of the deadly virus. However, India has developed a vaccine for COVID-19 and looks set to launch it for “public health use by August 15”.

“It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials,” the Indian Council of Medical Research said in a statement.

Covaxin, also known as BBV152 COVID vaccine, has been developed by the ICMR in partnership with Bharat Biotech International Limited. The clinical trials of this made-in-India vaccine have been termed as “priority project” and over a dozen of institutes have been selected for the task.

“The vaccine is derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the pre-clinical as well as clinical development of this vaccine,” the ICMR stated in a letter to the institutes.

The launch of the vaccine might get delayed only if the involved institutes fail to meet the timelines. However, the ICMR said in its letter that it will keep a check on “non-compliance” of the involved parties.

“Non-compliance will be viewed very seriously. Therefore, you are advised to treat this project on highest priority and meet the given timelines without any lapse,” the statement read further.

The institutes selected for the clinical trials are located in Visakhapatnam, Rohtak (Haryana), New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur (UP), Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.